Wednesday, November 19, 2014
Lincoln, Neb.-based Celerion, a provider of early-stage drug development solutions, and Ricerca Biosciences, which offer discovery, preclinical and development services, have formed “The Biosimilars Alliance,” focused on preclinical and early clinical assessment of biologics manufactured by a new supplier.
Ricerca Biosciences, a preclinical CRO, has partnered with Fulcrum Pharma, an Aptiv Solutions company and a provider of drug development consulting and regulatory services. The collaboration aims to help biopharmaceutical companies move a candidate from development to clinical evaluation more efficiently.
Numira Biosciences of Salt Lake City, Utah, a specialty CRO in high-resolution, 3D imaging services and visualization software for the life science market, has acquired the efficacy pharmacology unit of Ricerca Biosciences of Bothell, Wash. The acquisition adds a GLP-compliant facility with a range of laboratory capabilities to Numira, which will be able to offer in-life models and studies, high-resolution quantitative imaging, histology and immunohistochemistry services.
MDS completed its sale of the discovery and preclinical business of MDS Pharma Services, the company’s contract research organization (CRO). Under the terms of the deal, CRO Ricerca Biosciences of Concord, Ohio, acquired facilities in Bothell, Wash.; Lyon, France; and Taipei, Taiwan. Those facilities have 600 employees.
Although many companies are reducing headcount at an alarming rate, at least a few contract research organizations (CROs) continue to hire new people and create new positions. This week’s personnel news from around the clinical trial industry: